BROADCASTS.com

Every week, The American Journal of Managed Care\xae\xa0recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.\n\nThis week, the top managed care news included the FDA's approval of a $2.1 million gene therapy; a study revealing that the worldwide need for palliative care will nearly double by 2060; the FDA granting priority review to\xa0Amarin\u2019s Vascepa for\xa0a cardiovascular indication.\n\nRead more about the stories in this podcast:\nFDA Approves Gene Therapy With $2.1M Price Tag for Spinal Muscular Atrophy in Pediatric Patients: https://www.ajmc.com/newsroom/fda-approves-gene-therapy-with-21m-price-tag-for-spinal-muscular-atrophy-in-pediatric-patients\nSerious Health-Related Suffering to Nearly Double by 2060, Highlighting Need to Ramp Up Palliative Care Efforts: https://www.ajmc.com/focus-of-the-week/serious-healthrelated-suffering-to-nearly-double-by-2060-highlighting-need-to-ramp-up-palliative-care-efforts\nWhat We're Reading: FDA Grants Priority Review for Amarin's Vascepa; HHS Rule Challenged; Military Mental Health Proposal: https://www.ajmc.com/newsroom/what-were-reading-fda-grants-priority-review-for-amarins-vascepa-hhs-rule-challenged-military-mental-health-proposal\nAmarin's High-Dose Fish Oil Pill Cuts Total CV Event Risk 30% in Study: https://www.ajmc.com/conferences/acc-2019/amarins-highdose-fish-oil-pill-cuts-total-cv-event-risk-30-in-study\nThe American Journal of Managed Care\u2014May 2019: https://www.ajmc.com/journals/issue/2019/2019-vol25-n5\nOpen Doors to Primary Care Should Add a \u201cScreen\u201d to Reduce Low-Value Care: https://www.ajmc.com/journals/issue/2019/2019-vol25-n5/open-doors-to-primary-care-should-add-a-ldquoscreenrdquo-to-reduce-lowvalue-care\nAmerican Society of Clinical Oncology Annual Meeting 2019: https://www.ajmc.com/conferences/asco-2019